<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6079">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061034</url>
  </required_header>
  <id_info>
    <org_study_id>180/07</org_study_id>
    <nct_id>NCT01061034</nct_id>
  </id_info>
  <brief_title>Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers</brief_title>
  <official_title>The Effect of Proton Pump Inhibitor (Omeprazole) on Acetosalisylic Acid Absorption.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin is a weak acid that crosses the gastric and intestinal mucosa by passive diffusion
      while in its lipophilic nature.Omeprazole, a proton pump inhibitor, inhibits gastric acid
      secretion.

      We assumed that omeprazole inhibits aspirin absorption, thus reducing its action on
      platelets.

      healthy volunteers, with no known peptic disease or bleeding disorders will be enrolled.

      All volunteers will receive 7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin
      and Omeprazole 20mg twice daily for 3 days and then 20mg once daily.

      Blood levels of Aspirin will be determined by High performance liquid chromatography (HPLC),
      0, 1, 2, 4, 6, 10, 24 hours after the administration of Aspirin alone on day 7 and Aspirin
      plus Omeprazole on day 21.

      Platelet function tests will be determined by platelet-rich plasma aggregometry in response
      to Arachidonic acid (500mg/ml), Ristocetin (1.5mg/ml) and Adenosine 5'-diphosphate (20mM) on
      day 0 as baseline and on day 7 and 21 of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Aspirin Level in Blood (Area Under the Curve)</measure>
    <time_frame>on day 7,on day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Function Tests</measure>
    <time_frame>on day 0 as a baseline and on day 7 and 21 of the study.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Aspirin Blood Level</condition>
  <condition>Proton Pump Inhiditor Treatment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin and omeprazole</intervention_name>
    <description>aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -healthy volunteers

        Exclusion Criteria:

          -  pretreatment with aspirin

          -  pretreatment with non steroidal anti inflamatory drugs

          -  pretreatment with antacids

          -  history of peptic ulcer disease

          -  coagulation or aggregation disorder.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahuva golik, prop.</last_name>
    <role>Study Director</role>
    <affiliation>asaf-harofemedical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <lastchanged_date>January 2, 2010</lastchanged_date>
  <firstreceived_date>May 3, 2009</firstreceived_date>
  <firstreceived_results_date>May 3, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>dr. keren doenyas barak</name_title>
    <organization>internal medicine A asaf-harofeh medical center</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>aspirin</keyword>
  <keyword>proton pump inhiditor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>healthy volunteers were recruted on march 2007. all of the patients are co-workers in the department of medicine in assaf harofeh medical center.</recruitment_details>
      <pre_assignment_details>one volunteer was excluded before enrollment due to recent consumption of NSAIDS</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin Then Aspirin Plus Omeprazole</title>
          <description>7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole (20mg BID for 3 days and then 20mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Aspirin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Aspirin Plus Omeprazole</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin Then Aspirin Plus Omeprazole</title>
          <description>7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole (20mg BID for 3 days and then 20mg once daily</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.3" spread="12.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aspirin Level in Blood (Area Under the Curve)</title>
        <description>Aspirins pharmacokinetics: aspirin blood level determined by use of high performance liquid chromatography (HPLC) at baseline, 1, 2,4,6,10 and 24 hours after administration of aspirin on day 7 and on day 21.
The area unther the time vs. concentration curve of the reccurent measurments(AUC) reflects bioavailability of aspirin.</description>
        <time_frame>on day 7,on day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>9 volunteers completed the study, one volunteer was excluded from pharmacokinetics, because serum salicylic acid concentration was not at the baseline (non-detectable) in the 0-hour sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin Then Aspirin Plus Omeprazole</title>
            <description>7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole (20mg BID for 3 days and then 20mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Aspirin Level in Blood (Area Under the Curve)</title>
            <description>Aspirins pharmacokinetics: aspirin blood level determined by use of high performance liquid chromatography (HPLC) at baseline, 1, 2,4,6,10 and 24 hours after administration of aspirin on day 7 and on day 21.
The area unther the time vs. concentration curve of the reccurent measurments(AUC) reflects bioavailability of aspirin.</description>
            <units>mg*hour/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>aspirin area under the curve on day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49.4" spread="13.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>aspirin area under the curve on day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.7" spread="15.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 hour after admission day 7 (aspirin alone)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.7" spread="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 hour after admission day 21 (aspirin+omeprazole)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.5" spread="4.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Function Tests</title>
        <description>Platelet function tests were determined by optical whole blood aggregometry in response to arachidonic acid and adenosine diphosphate.
the results reflects the percent of active platelets.</description>
        <time_frame>on day 0 as a baseline and on day 7 and 21 of the study.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aspirin Then Aspirin Plus Omeprazole</title>
            <description>7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole (20mg BID for 3 days and then 20mg once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Platelet Function Tests</title>
            <description>Platelet function tests were determined by optical whole blood aggregometry in response to arachidonic acid and adenosine diphosphate.
the results reflects the percent of active platelets.</description>
            <units>percent</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80" spread="4.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.55" spread="2.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.77" spread="2.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aspirin Then Aspirin Plus Omeprazole</title>
          <description>7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole (20mg BID for 3 days and then 20mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mild dyspepsia</sub_title>
                <description>one volunteer complained mild dyspepsia unther aspirin treatment alone. his complaine resolved withoud any special intervention.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Keren Doenyas-Barak</name_or_title>
      <organization>Assaf Harofeh medical center</organization>
      <phone>972-57-7346651</phone>
      <email>kerendoenyas@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
